文献速递脑血管病认知障碍与痴呆

RVCL-S 神经影像生物标志物与认知变化

Neuroimaging Biomarkers of Disease Progression and Cognitive Change in Patients With Retinal Vasculopathy With Cerebral Leukoencephalopathy.
PubMed 文献 · Neurology · 2026-02-20

本研究前瞻性随访 25 例 RVCL-S 患者,中位 2.2 年内所有影像和认知终点(除 MoCA)均进展,WMH 体积年增 31.3%,DSST 每十年下降 13.1 分。氧摄取分数(OEF)独立与 WMH 增长和白质微结构改变相关,提示组织缺氧缺血参与病理生理。

要点

  • RVCL-S 患者 WMH 体积年增长 31.3%,进程迅速。
  • DSST 每十年下降 13.1 分,处理速度衰退最显著。
  • OEF 升高独立预测 WMH 增长和白质微结构恶化。

核心结论

  • OEF 升高与 WMH 进展和白质微结构损伤独立相关,提示缺氧缺血机制。
  • OEF 有望作为 RVCL-S 及其他 cSVD 的风险分层预测生物标志物。

研究设计与样本

  • 前瞻性 RVCL-S 队列,25 例患者年龄 23-68 岁(中位 47 岁,56% 女性),中位随访 2.2 年完成 151 次扫描。
  • 序列脑 MRI 包括动脉自旋标记和不对称自旋回波定量 CBF 与 OEF,并完成认知 battery。
  • 线性混合效应模型分析年龄、CBF、OEF 与影像和认知进展的关联。

主要发现

  • 所有影像和认知终点随时间进展,但 MoCA 除外。
  • WMH 体积年变化率最大(+31.3%/年,95% CI 20.8%-42.3%)。
  • DSST 下降最陡(-13.1 T 分/十年,95% CI -21.2 至 -5.32),自由回忆和类别流畅性分别下降 5 和 4.1 T 分/十年。
  • 首次脑病灶估计年龄为 30.6 岁(95% CI 23.8-35.8),基于个体 WMH 轨迹建模。
  • 多变量分析中 OEF 独立与 WMH 增长(β=3.73,95% CI 0.63-6.83,p=0.029)和白质微结构改变(β=0.175,95% CI 0.029-0.32,p=0.029)相关,CBF 无此关联。

关键数值与推荐

  • WMH 体积年变化率 +31.3%(95% CI 20.8%-42.3%)。
  • DSST 每十年下降 -13.1 T 分(95% CI -21.2 至 -5.32)。
  • OEF 与 WMH 增长的 β=3.73(95% CI 0.63-6.83,p=0.029)。
  • OEF 与白质微结构改变的 β=0.175(95% CI 0.029-0.32,p=0.029)。

临床怎么用

  • 脑 OEF 可作为 RVCL-S 疾病进展的预测生物标志物,用于风险分层。
  • WMH 体积和 DSST 可能作为监测疾病进展的敏感终点。

局限性

  • 样本量小(25 例),随访时间有限。
  • OEF 和 CBF 未独立关联认知下降,机制需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: A monogenic, age-related cerebral small vessel disease (cSVD), retinal vasculopathy with cerebral leukoencephalopathy and systemic manifestations (RVCL-S), causes accelerated vascular dementia, vision loss, and premature death. Given knowledge is limited regarding its pathophysiology, we examined the natural history of progression in imaging and cognitive endpoints to define the rate and variability of progression in a prospective RVCL-S cohort. We hypothesized that cerebral blood flow (CBF) and oxygen extraction fraction (OEF), as metrics of cerebral hypoxia-ischemia, would be associated with neurologic disease progression. METHODS: We performed sequential brain MRI and a cognitive battery in a prospective RVCL-S cohort. Arterial spin labeling and asymmetric spin echo quantified CBF and OEF in normal-appearing white matter (WM), respectively. Three neuroimaging endpoints of cSVD included the following: log-transformed, normalized fluid-attenuated inversion recovery WM hyperintensity (WMH) volume; WM microstructure using mean diffusivity; and normalized WM volume. Five cognitive and motor endpoints included Digit Symbol Substitution Test (DSST), category fluency, free recall, Montreal Cognitive Assessment (MoCA), and gait speed. Linear mixed-effects models examined age, CBF, and OEF in association with neuroimaging and cognitive progression. RESULTS: Twenty-five participants, aged 23-68 years (median 47 years, 56% female), underwent 151 scans over a median (25th, 75th) of 2.2 (1.8, 4.4) years. All neuroimaging and cognitive endpoints progressed over time, except for MoCA. Of neuroimaging endpoints, WMH volume demonstrated the largest rate of change (+31.3%/year, 95% CI 20.8%-42.3%). Of cognitive endpoints, DSST, a metric of processing speed, showed the steepest decline (-13.1 T-score points/decade, 95% CI -21.2 to -5.32), followed by free recall and category fluency (-5 [-7.9 to -2.4] and -4.1 [-7.2 to -1.2] T-score points per decade, respectively). The age at first brain lesion was estimated to be 30.6 (23.8, 35.8) years, modeled from individual WMH volume trajectories. In multivariable analysis, OEF, but not CBF, was independently associated with WMH growth (β = 3.73, 95% CI 0.63-6.83, p = 0.029) and change in WM microstructure (β = 0.175, 95% CI 0.029-0.32, p = 0.029). Neither OEF nor CBF was independently associated with cognitive decline. DISCUSSION: Elevated OEF in at-risk WM was associated with progression in WMH and impairment in WM microstructure, suggesting a role for tissue hypoxia-ischemia in underlying RVCL-S pathophysiology. Cerebral OEF holds promise as a predictive biomarker to risk-stratify patients with RVCL-S and other forms of cSVD.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Ford AL, Kang P, Fellah S, et al. Neuroimaging Biomarkers of Disease Progression and Cognitive Change in Patients With Retinal Vasculopathy With Cerebral Leukoencephalopathy. Neurology. 2026. PMID: 41719494. doi:10.1212/WNL.0000000000214703

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。